Guangdong VTR Bio-Tech Co Ltd

Guangdong VTR Bio-Tech Co Ltd has a market price of 7.22 CNY per share, with a market capitalization of 3.55 billion CNY. The company's price-to-book ratio is 1.39, and its price-to-tangible-book ratio is also 1.39, indicating that the market values the company slightly above its book value. The enterprise value to EBITDA ratio is negative at -227.01, reflecting the company's current operating losses. The enterprise value to revenue ratio is 4.35, suggesting that the company is valued at 4.35 times its annual revenue. The company's profitability metrics are weak, with a return on equity of -0.78% and a return on assets of -0.68%, both of which are below the industry median for biotechnology firms. The gross profit margin is 43.98%, calculated as 366.24 million CNY in gross profit divided by 832.26 million CNY in revenue. However, the company reported an operating loss of 15.96 million CNY and a net loss of 19.78 million CNY, indicating significant operational challenges. Geographically and segment-wise, the company's revenue concentration is not disclosed in the available data. The company operates in the biotechnology industry, which is characterized by high R&D intensity and long development cycles. The lack of segment-specific revenue data limits the ability to assess geographic or product diversification. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The operating cash flow is positive at 121.07 million CNY, but the free cash flow is negative at -221.73 million CNY, primarily due to capital expenditures of -277.23 million CNY. This suggests that the company is investing heavily in its operations, which could be a sign of expansion or R&D activities. The company faces several risk factors, including a medium liquidity risk and a low dilution risk. The key flag of concern is the negative net cash position after subtracting total debt, which could impact the company's ability to meet short-term obligations. The debt-to-equity ratio is 0.03, indicating a relatively low level of leverage. The current ratio of 3.97 suggests that the company has sufficient current assets to cover its current liabilities. Recent events and filings do not provide specific details on the company's strategic initiatives or major developments. The company's financial performance and operational challenges suggest that it is in a development or growth phase, which is typical for biotechnology firms.